Pfizer Inc. has been questioned as a potential buy given the growth driven by its COVID-related products during its fourth quarter. Despite EPS soaring 530% in Q4, shares fell, a pattern that followed for vaccine stocks. The firm's cost cuts and consistent COVID sales resulted in profit growth, although some investors elected to decrease their stake in the company. Both Q4 revenue and earnings beat predictions which brought optimism that growth may accelerate further. However, the sustainability of their Covid product-driven profits remains uncertain. Despite the stock taking some hits, Pfizer recorded an impressive increase in its non-COVID portfolio by 21% in Q4. With a stake in Pfizer now considered a prime dividend stock with a 5% yield, it represents one of the best dividend stocks under $30. Some critics, such as Goldman Sachs, have reduced their price target for Pfizer. Despite the fluctuations, it is considered among the most promising cancer stocks to buy by hedge funds. The firm saw mixed reviews for performance, with some dropping shares while others increased their stockholdings. The outlook for Pfizer's shares in 2025 is generally optimistic, but the firm still has some challenges to overcome.
Pfizer Stocks News Analytics from Fri, 15 Nov 2024 08:00:00 GMT to Sat, 08 Feb 2025 22:42:22 GMT - Rating 2 - Innovation 0 - Information 6 - Rumor -3
